• Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • You are here:
  • Home
  • Insights
  • Ecotoxicological assessment of pharmaceuticals and personal care products using predictive toxicology approaches

Ecotoxicological assessment of pharmaceuticals and personal care products using predictive toxicology approaches

With their widespread and ever increasing use, active pharmaceutical ingredients (API) and personal care products (PCP) represent contaminants of emerging concern for the aquatic and terrestrial environments. Today, numerous countries worldwide have issued regulations and guidance to cover the environmental risk assessment of these substances, but in many cases the necessary hazard data is missing or incomplete.

In their comprehensive review, Kar et al. (2020) first present a qualitative and quantitative overview of the pharmaceuticals and PCPs (globally referred to as ‘PPCPs’) of highest environmental concern, then discuss how predictive toxicology approaches can be applied to complement hazard data packages, but also to design environmentally friendlier PPCPs.

Commonly found APIs in the environment include a number of antibiotics, beta-blockers, analgesics and non-steroidal inflammatory drugs (NSAIDs), antineoplastic/anticancer compounds, blood-lipid lowering agents, CNS acting drugs, antiviral and anti-parasitic drugs, hormones and metabolites of the above. Frequently detected PCPs are in the categories of disinfectants and bactericides, fragrances, insect repellants, preservatives and UV filters/sunscreen agents. Because most PCPs are designed for external use, metabolic changes inside the body are less relevant for these substances.

The use of in silico tools to predict the hazardous properties of PPCPs is growing, in line with the efforts to reduce animal testing in toxicology and ecotoxicology.  Predictive tools comprise QSTR (quantitative structure-toxicity relationship models, i.e. (Q)SAR systems in which the toxicity endpoints are modelled and predicted), interspecies QSTR (i-QSTR/QTTR) models, read-across, pharmacophore (toxicophore)-based approaches and molecular docking applications. An array of expert systems for the prediction of chemical toxicities also exists, built upon experimental data and/or rules derived from such data (e.g. OECD (Q)SAR Toolbox, ECOSAR, CATALOGIC, etc.).

Kar and collaborators review the main endpoints for in silico modelling of ecotoxicity as well as existing ecotoxicity databases in relation to PPCPs. The authors then critically analyze SAR and (Q)SAR studies for ecotoxicological assessment of PPCPs (e.g. existing models, imperative features responsible for ecotoxicity and fate) and finally discuss challenges such as mixture toxicity and the impact of metabolism.

This publication, written a series of experts in the field, is a very good source of useful data on PPCPs in the environment, environmental risk assessment methodologies across various regions, existing in silico tools/databases for environmental endpoints, comprising detailed information and concrete examples.

Author
  • Dr. Francesca Tencalla

    Dr. Francesca Tencalla

MORE INSIGHTS
  • Natural ingredients, inherently safe?

  • Developments on the identification of potential endocrine disruptors under EU legislation

  • Joint EFSA/ECHA guidance document for the identification of endocrine disruptors under EU Biocides and Pesticides Regulation

Nanomaterials in cosmetics – The next priority of the Commission?

Previous thumb

The European Commission’s Joint Research Centre (EC- JRC) tender to collect and organise mechanistic knowledge related to the toxicological effects on target organs observed in animal models after repeated exposure to chemicals

Next thumb
Scroll

 

ToxMinds are specialised in ensuring product safety and compliance.

We are passionate about toxicology and how emerging scientific developments can be utilised to support our customers in bringing safe, regulatory compliant and sustainable products to the marketplace.

 

 

 

 

Belgium
ToxMinds BV
Avenue de Tervueren 188A, bte 12
B-1150 Brussels Belgium

VAT BE 0877.628.383

Tel: +32 (0)2 762 9145
Email: contact us

 

 

 

 

India
ToxMinds India Consulting Pvt. Ltd.
Unit 305, 3rd Floor, Brigade IRV Centre, Whitefield, Bangalore-560066, India

 

Tel: +91 804 204 19 20
Email: contact us

 

 

 

 

 

LinkedIN
Copyright and disclaimer | Data privacy
  • Home
  • Industries
  • Services
  • Team
  • Insights
  • Careers
  • Contact
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok